Context Therapeutics grants 270K options to CLO

Levit Alex C. reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 02/23/2026 - 04:24 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Levit Alex C. reported acquisition or exercise transactions in this Form 4 filing.

Context Therapeutics Inc. reported that Chief Legal Officer and Corporate Secretary Alex C. Levit received a grant of stock options covering 270,000 shares on February 19, 2026. According to the terms, 25% of the options vest on February 19, 2027, with the remainder vesting in equal monthly installments over the following three years, conditioned on continued service.

Insider Trade Summary

Grant/Award: 270,000 shares

Grant/Award 1 txn

Insider Levit Alex C.

Role Chief Legal Officer, Corp. Sec

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	270,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 270,000 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 270,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CNTX report for Alex C. Levit?

Context Therapeutics reported a stock option grant to Alex C. Levit covering 270,000 shares. The options were awarded on February 19, 2026 as part of his compensation, subject to a multi-year vesting schedule tied to continued service with the company.

How many CNTX shares are covered by Alex C. Levit’s new stock options?

The new stock option grant covers 270,000 Context Therapeutics shares. This represents potential future ownership rather than immediate share acquisition, since the options must vest over time and then be exercised to convert into actual common stock.

What is the vesting schedule for Alex C. Levit’s CNTX stock options?

The options vest over four years. Twenty-five percent vest and become exercisable on February 19, 2027, while the remaining 75% vest in equal monthly installments over the next three years, contingent on his continued service with Context Therapeutics.

Is Alex C. Levit’s CNTX stock option transaction a purchase or a grant?

This transaction is a grant of stock options, not an open-market purchase. The Form 4 labels it as a grant, award, or other acquisition, providing potential future rights to buy shares subject to vesting and later exercise.

Does Alex C. Levit directly own the CNTX stock options reported?

Yes. The Form 4 classifies the ownership of these stock options as direct. That means the options are held in his name rather than through an indirect vehicle such as a trust, partnership, or other affiliated entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levit Alex C.

(Last) (First) (Middle)

2001 MARKET STREET

SUITE 3915, UNIT #15

(Street)

PHILADELPHIA PA 19103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Context Therapeutics Inc. [ CNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer, Corp. Sec

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.32	02/19/2026		A		270,000		(1)	02/18/2036	Common Stock	270,000	$0	270,000	D

Explanation of Responses:

1. The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Remarks:

	/s/ Alex Levit, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.